



Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease

March 6, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2019-- [Synlogic, Inc.](#), (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its collaboration with [AbbVie](#), a global biopharmaceutical company, to develop an oral treatment for inflammatory bowel disease (IBD).

"We are delighted with the progress of our collaboration with AbbVie, a world-class company with expertise in immunology and the development of treatments for patients with inflammatory bowel disease," said Aoife Brennan, M.B. Ch.B., Synlogic's president and chief executive officer "Our collaboration has enabled us to broaden the reach of our platform in inflammatory and autoimmune conditions while advancing our internal pipeline in rare metabolic diseases."

"Synlogic is a leader in the use of synthetic biology for the development of novel bacterial therapeutics," said, Lisa Olson Ph.D., Vice President, Immunology Research, AbbVie. "Synlogic's Synthetic Biotic platform has the potential to enable development of treatments for inflammatory disorders, such as IBD. We are pleased with the progress that our combined teams continue to make in the development of this novel approach."

About Synlogic

Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease. Synthetic Biotic medicines are designed to act locally and have a systemic effect to address disease in patients. Synlogic's two lead programs, SYNB1020 and SYNB1618, are orally administered and target hyperammonemia as a result of liver damage or genetic disease, and phenylketonuria, respectively. Synlogic is also developing SYNB1891 as an intratumorally-administered Synthetic Biotic medicine for the treatment of cancer. In addition, the company is leveraging the broad potential of its platform to create additional Synthetic Biotic medicines for the treatment of liver disease, as well as inflammatory and immune disorders including Synlogic's collaboration with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases, including: inflammatory and immune disorders, rare metabolic diseases, liver disease and cancer; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the potential of Synlogic's technology to treat cancer, hyperammonemia, and phenylketonuria. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190306005188/en/>

Source: Synlogic, Inc.

MEDIA CONTACT:

Courtney Heath
Phone: 617-872-2462
Email: courtney@scientpr.com

INVESTOR CONTACT:

Elizabeth Wolffe, Ph.D.
Phone: 617-207-5509
Email: liz@synlogictx.com